CSL Seqirus shipped innovative influenza vaccines for the 2023/24 U.S. season

On July 17, 2023, CSL Seqirus had announced that it had commenced shipping its portfolio of innovative cell-based, adjuvanted, and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company positioned itself to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.

Dr. Gregg Sylvester, Chief Health Officer at CSL Seqirus, emphasized, “Last season underscored the devastating impact flu can have, with over 300,000 flu-related hospitalizations and 19,000 flu-related deaths reported based on preliminary data through April 2023.” Dr. Sylvester also highlighted the importance of raising immunization rates to protect individuals from influenza and its potentially life-threatening complications.

CSL Seqirus stood out as the sole manufacturer offering differentiated influenza vaccine options approved for use in individuals six months of age and older. The portfolio for the 2023/24 U.S. influenza season included:

– **FLUCELVAX® QUADRIVALENT (Influenza Vaccine):** The first and only cell-based quadrivalent influenza vaccine indicated for use in people six months and older. It provided an exact antigenic match to the World Health Organization-selected influenza virus strains.

– **FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted):** The first and only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 years and older. It contained an MF59® adjuvant designed to strengthen the immune response.

– **AFLURIA® QUADRIVALENT (Influenza Vaccine):** An egg-based, quadrivalent influenza vaccine approved for use in eligible people six months of age and older.

CSL Seqirus aimed to work with public health partners to drive influenza vaccination rates back up to pre-pandemic levels. The company’s commitment was focused on reducing flu-related hospitalizations and the overall burden of disease.

Influenza, a common, contagious seasonal respiratory disease, had shown potential to cause severe illness and life-threatening complications. Preliminary estimates from the Centers for Disease Control and Prevention (CDC) indicated significant influenza-related hospitalizations during the 2022/23 season. Annual vaccination was recommended for individuals aged 6 months and older, and vaccination before influenza spread in the community was emphasized.